AIM ImmunoTech Inc.

Snapshot

AIM ImmunoTech is a micro-cap biotech in financial distress. The company generated only $88K in revenue in FY 2025, a 48% drop from the prior year, while losing $14.0M in net income. Its cash position is critically tight, with just $993K in cash against $4.9M in debt, resulting in a cash runway of only 3.1 months at current burn rates. To survive, the company has been aggressively raising capital through dilutive equity offerings and warrant exercises, including a recent $2.4 million financing and a $4.2 million warrant exercise.

What's Happening Right Now

• Mon 1st Jun '26 · Clinical Trial: AIM completed enrollment in its Phase 2 pancreatic cancer study ahead of schedule, with the final subject scheduled for treatment in mid-June 2026.
• Wed 20th May '26 · Capital Raise: The company announced a $2.4 million financing via a registered direct offering and private placement to fund clinical trials and working capital.
• Fri 8th May '26 · Warrant Exercise: Investors exercised outstanding warrants for approximately $4.2 million in gross proceeds, providing additional cash for general corporate purposes.
• Thu 7th May '26 · Trial Data: The company reported a 50% objective response rate in a Phase 2 ovarian cancer trial combining Ampligen with other therapies.
• Mon 13th Apr '26 · Going Concern: Auditors issued a going-concern emphasis of matter for FY 2025, signaling serious doubt about the company's ability to continue operating.